## SUPPLEMENTARY MATERIALS

## MODELLING OF TIME-TO-EVENTS IN AN AMBISPECTIVE STUDY: ILLUSTRATION WITH THE ANALYSIS OF $A B O$ BLOOD GROUPS ON VENOUS THROMBOSIS RECURRENCE

Gaëlle Munsch, Louisa Goumidi, Astrid van Hylckama Vlieg, Manal Ibrahim-Kosta, Maria Bruzelius, JeanFrançois Deleuze, Frits R. Rosendaal, Hélène Jacqmin-Gadda, Pierre-Emmanuel Morange, David-Alexandre Trégouët

## CONTENTS:

Supplementary Figures 1-6 2
Supplementary Tables 1-3 5
Supplementary Text 8

Supplementary Figure S1. Flow chart of the MARTHA sub-samples


Supplementary Figure S2. Distribution of the age at enrolment in MARTHA participants ( $\mathrm{N}=1,504$ )


Supplementary Figure S3. Distribution of the delay between enrolment and the first VT in MARTHA participants $(\mathrm{N}=1,504)$


Supplementary Figure S4. Kaplan Meier plot of the survival probability in MARTHA participants with an available follow up ( $\mathrm{N}=1,380$ including 73 deaths)


Supplementary Figure S5. Distribution of the estimated weights for the MARTHA participants ( $\mathrm{N}=1,504$ )


Supplementary Figure S6. Sensitivity of the association of $A B O$ blood groups with recurrence according to the weights estimation in MARTHA ( $\mathrm{N}=1,504$ )


[^0] Text). The dashed line corresponds to the estimated value in the initial model

Supplementary Table S1. Description of the MARTHA sample for the death risk estimation

| Variables | Total <br> $\mathbf{N = 1 , 3 8 0}$ |
| :--- | :--- |
| $\mathbf{N ( \% )}$ |  |
| Gender <br> $\quad$ Men <br> Age at inclusion (mean $\pm$ Standard Deviation (SD)) | $47.1 \pm 15.3$ |
| Age at the first VT (mean $\pm$ SD) | $41.3 \pm 15.7$ |
| Delay between inclusion and first VT <br> (In years, mean $\pm$ SD) | $5.8 \pm 9.6$ |
| Type of the first VT <br> $\quad$ DVT only | $1,087(78.8 \%)$ |
| Characteristic of the first VT | $911(66.0 \%)$ |
| $\quad$ Provoked | $11.8 \pm 5.3$ |
| Delay of follow-up in years* <br> (In years, mean $\pm$ SD) |  |

[^1]Supplementary Table S2. Association of ABO haplotypes with first VT recurrence in MARTHA ambispective and MEGA stratified on the type of the first VT

| Variables | MARTHA Ambispective $\mathbf{N}=\mathbf{1 , 5 0 4}$ <br> Nb recurrences $=565$ |  | MEGA$\mathrm{N}=1,248$Nb recurrences $=428$ |  | Meta-Analysis Fixed-effects |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | HR (95\% CI) | P | HR (95\% CI) | P | HR (95\% CI) | P |
| ABO haplotypes - PE as first VT | $\mathbf{N}=\mathbf{3 1 5}$; 111 rec | rrences | $\mathbf{N}=\mathbf{4 8 5}$; 158 recc | rrences |  |  |
| A1 | 1.10 (0.82-1.48) | 0.536 | 1.38 (1.05-1.82) | 0.020 | 1.24 (1.02-1.51) | 0.029 |
| A2 | 1.87 (1.04-3.37) | 0.039 | 0.79 (0.49-1.27) | 0.329 | 1.11 (0.80-1.55) | 0.554 |
| O1 | Refere |  | Referenc |  | Reference |  |
| O2 | 0.65 (0.13-3.24) | 0.600 | 0.70 (0.28-1.72) | 0.434 | 0.69 (0.36-1.32) | 0.250 |
| B | 0.85 (0.47-1.53) | 0.574 | 0.83 (0.51-1.36) | 0.447 | 0.84 (0.59-1.20) | 0.318 |
| ABO haplotypes - DVT as first VT | $\mathrm{N}=1,189$; 454 re | urrences | $\mathrm{N}=763$; 270 rec | rences |  |  |
| A1 | 1.16 (0.99-1.36) | 0.063 | 1.14 (0.94-1.39) | 0.211 | 1.15 (1.00-1.32) | 0.045 |
| A2 | 1.20 (0.91-1.58) | 0.180 | 1.29 (0.94-1.77) | 0.104 | 1.24 (1.00-1.54) | 0.059 |
| O1 | Refere |  | Referenc |  | Reference |  |
| O2 | 1.41 (0.85-2.35) | 0.180 | 0.94 (0.46-1.90) | 0.872 | 1.23 (0.75-2.01) | 0.422 |
| B | 1.06 (0.84-1.34) | 0.612 | 1.08 (0.79-1.48) | 0.637 | 1.07 (0.86-1.33) | 0.566 |

HR: Hazard Ratio
CI: Confidence Interval

Supplementary Table S3. Definition of the provoked character in MARTHA and MEGA

| MARTHA study | MEGA study |
| :---: | :---: |
| - Surgery within 3 months before VT | - Surgery within 3 months before VT |
| - Pregnancy/ puerperium within 3 months before VT | - Pregnancy/ puerperium within 3 months before VT |
| - Oral contraceptive use within 3 months before VT | - Hormone use at the time of VT, including: hormone replacement therapy and hormonal contraceptives |
|  | - Plaster cast within 3 months before VT |
| - Immobilization for 7 days or more within 3 months before VT | - Immobility in bed, in hospital: Confinement to bed $\geq 3$ days in hospital, confinement to bed $\geq 3$ days at home, within 3 months before VT |
| - Long travel (by car >10 hours; by plane > 5 hours) within 3 months before VT | - Prolonged travel >4 hours within 2 months before VT |
| - Trauma of the lower limb within 3 months before VT | - Leg injury in 3 months before VT |
| - Pneumonia in year before VT | - Pneumonia in year before VT |
| - Infection in year before VT (urinary tract infection, pyelonephritis, arthritis, bursitis, sinusitis, pulpitis, inflammation elsewhere, hepatitis $\mathrm{A}, \mathrm{B}$ or C ) | - Infection in year before VT (urinary tract infection, pyelonephritis, arthritis, bursitis, sinusitis, pulpitis, inflammation elsewhere, hepatitis A, B or C) |

## Supplementary Text. Sensitivity analysis on the weights estimation for MARTHA participants

Methods: To investigate the variability of the weights estimated from the MARTHA study and their impact on the weighted Cox model, we used a Monte Carlo method. From the death risk model, we estimated the survival function $\hat{S}\left(t_{i} \mid Z_{i}\right)=\exp \left(-\hat{A}\left(t_{i} \mid Z_{i}\right)\right)$ of each individual $i$ up to the time $t_{i}$ (which corresponds to the time of collection of the information on VT recurrence). Assuming that the cumulative risk $\hat{A}\left(t_{i} \mid Z_{i}\right)$ follows a normal distribution, for each individual we randomly draw 1,000 values of the his/her cumulative risk from the distributions $N\left(\hat{A}\left(t_{i} \mid Z_{i}\right), S E\left(\hat{A}\left(t_{i} \mid Z_{i}\right)\right)\right.$ ) and computed the corresponding survival probabilities $\hat{S}_{k}\left(t_{i} \mid Z_{i}\right)=$ $\exp \left(-\hat{A}_{k}\left(t_{i} \mid Z_{i}\right)\right)$ to obtain the set of individual weights $w_{i k}$ for $\mathrm{k}=1, \ldots, 1000$. Then 1,000 weighted Cox model for the VT recurrence were estimated.

Results: The distributions of the HR for the ABO blood groups from the 1,000 models for VT recurrence are shown in Supplementary Figure 6 where the value of the HR estimated in the initial model is presented as a dashed line. The empirical distributions are well centred at the initial estimated HRs and, for both A1 and A2, all estimated HRs are above 1 supporting our conclusions.


[^0]:    Note: The 4 panels show the distribution of the Hazard Ratio in the Monte Carlo resampling analysis (See Supplementary

[^1]:    *According to the death event

